Crude, adjusted and imputed HR rate with 95% CIs for the secondary outcome: myocardial infarction (ICD-10: MI2), ischaemic stroke (ICD-10: I63) and unspecified stroke (ICD-10: I64) and coronary artery bypass grafting (ICD-10 code: I25.810) and percutaneous coronary intervention (ICD-10 code: I21.A9) among 42 257 patients undergoing their first non-contrast-enhanced cardiac CT examination due to incident chest pain in Denmark, 2008–2016
| Exposure | N | Events in follow-up | Rate per 1000 person-years (95% CI) | HR, crude (95% CI) | HR, adjusted* (95% CI) | Imputed† 95% CI |
| Overall | ||||||
| Not RA | 41899 | 1208 | 8.2 (7.8 to 8.7) | 1 | 1 | 1 |
| RA | 358 | 18 | 15.7 (9.9 to 24.9) | 1.40 (0.70 to 2.81) | 1.88 (1.08 to 3.26) | 1.58 (0.99 to 2.52) |
| Serology | ||||||
| Not RA | 41 899 | 208 | 8.2 (7.8 to 8.7) | 1 | 1 | 1 |
| Seropositive RA | 280 | 16 | 18.1 (11.1 to 29.6) | 1.88 ((1.33 to 3.58) | 1.42 (0.93 to 2.16) | 1.79 (1.03 to 3.10) |
| Other RA | 78 | 2 | 7.6 (1.9 to 30.2) | 0.92 (0.22 to 3.66) | 1.15 (0.51 to 2.56) | 0.82 (0.20 to 3.32) |
| Flare treatment | ||||||
| Not RA | 41 899 | 1208 | 8.2 (7.8 to 8.7) | 1 | 1 | 1 |
| No joint injection‡ | 215 | 8 | 11.7 (5.8 to 23.3) | 1.40 ((0.77 to 2.81) | 1.27 (0.60 to 2.67) | 1.17 (0.58 to 2.34) |
| ≥1 joint injections§ | 143 | 10 | 21.6 (11.6 to 40.2) | 2.62 (1.40 to 4.89) | 1.92 (0.95 to 3.86) | 2.21 (1.18 to 4.13) |
| Treatment escalation | ||||||
| Not RA | 41 899 | 1208 | 8.2 (7.8 to 8.7) | 1 | 1 | 1 |
| csDMARD¶ | 257 | 14 | 17.0 (10.1 to 22.7) | 2.05 (1.21 to 3.47) | 1.64 (0.93 to 2.91) | 1.63 (0.96 to 2.76) |
| bDMARD** | 101 | 4 | 12.3 (4.6 to 32.8) | 1.48 (0.55 to 3.96) | 1.26 (0.40 to 3.93) | 1.43 (0.54 to 3.83) |
*Adjusted for sex, age, comorbidity, hypertension, lipid-lowing treatment, BMI, smoking
†Imputation of missing values for BMI and smoking.
‡0 joint injection within 3 years prior to cardiac CT.
§>1 joint injection within 3 years prior to cardiac CT.
¶Patients exclusively treated with csDMARDs.
**Patients treated with a bDMARD at any time during the disease course.
bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; MI2, multiple imputation 2; RA, rheumatoid arthritis.